Sanò, M.V.; Russo, A.; Marino, L.; Pafumi, S.; Di Pietro, M.; Ricciardi, G.R.R.
Could 18F-FES PET Be a New Driver in Therapeutic Choice for Metastatic HR+/HER2− Patients? Diagnostics 2025, 15, 2139.
https://doi.org/10.3390/diagnostics15172139
AMA Style
Sanò MV, Russo A, Marino L, Pafumi S, Di Pietro M, Ricciardi GRR.
Could 18F-FES PET Be a New Driver in Therapeutic Choice for Metastatic HR+/HER2− Patients? Diagnostics. 2025; 15(17):2139.
https://doi.org/10.3390/diagnostics15172139
Chicago/Turabian Style
Sanò, Maria Vita, Alessandro Russo, Lorenza Marino, Sarah Pafumi, Martina Di Pietro, and Giuseppina Rosaria Rita Ricciardi.
2025. "Could 18F-FES PET Be a New Driver in Therapeutic Choice for Metastatic HR+/HER2− Patients?" Diagnostics 15, no. 17: 2139.
https://doi.org/10.3390/diagnostics15172139
APA Style
Sanò, M. V., Russo, A., Marino, L., Pafumi, S., Di Pietro, M., & Ricciardi, G. R. R.
(2025). Could 18F-FES PET Be a New Driver in Therapeutic Choice for Metastatic HR+/HER2− Patients? Diagnostics, 15(17), 2139.
https://doi.org/10.3390/diagnostics15172139